Rozanolixizumab (Rystiggo)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses rozanolixizumab (Rystiggo), 140 mg/mL, solution for injection (280 mg in 2 mL in single-dose glass vials) for SC use. Indication: For the treatment of adult patients with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase inhibitor antibody positive.